



## Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February

February 9, 2017

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets, today announced its participation in two investor conferences during the month of February.

### The 19<sup>th</sup> Annual BIO CEO & Investor Conference

On Tuesday, February 14, 2017, Susan Molineaux, Ph.D., Founder, President and Chief Executive Officer, will present a corporate update at 11:30 a.m. EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.

### Leerink Global Healthcare Conference

On Wednesday, February 15, 2017, Dr. Molineaux will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 1:00 p.m. EST.

These presentations will be webcast live and available for replay for up to 30 days at [www.calithera.com](http://www.calithera.com) in the Investor Relations section.

### About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body's cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a Phase I clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit [www.calithera.com](http://www.calithera.com).

### Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the Company's clinical pipeline of novel cancer therapies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at [www.sec.gov](http://www.sec.gov). These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Contact:

Jennifer McNealey

[ir@Calithera.com](mailto:ir@Calithera.com)

650-870-1071

 [Primary Logo](#)

Calithera Biosciences, Inc.